BETHESDA, Md. - Protein Science Inc.'s goal of being the first company in the U.S. to gain approval of a cell-based flu vaccine may have been dashed Thursday after an FDA panel said FluBlok's safety data were insufficient and the efficacy data would only support approval in adults 18 to 49 years, but not older patients. (BioWorld Today) Read More
